As of 2025-07-05, the EV/EBITDA ratio of Urogen Pharma Ltd (URGN) is -4.97. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. URGN's latest enterprise value is 645.03 mil USD. URGN's TTM EBITDA according to its financial statements is -129.91 mil USD. Dividing these 2 quantities gives us the above URGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.1x - 7.6x | 6.4x |
| Forward P/E multiples | 6.2x - 9.2x | 7.7x |
| Fair Price | (17.76) - (21.88) | (20.20) |
| Upside | -230.8% - -261.1% | -248.8% |
| Date | EV/EBITDA |
| 2025-07-03 | -4.97 |
| 2025-07-02 | -4.75 |
| 2025-07-01 | -4.77 |
| 2025-06-30 | -5.01 |
| 2025-06-27 | -4.93 |
| 2025-06-26 | -4.80 |
| 2025-06-25 | -5.01 |
| 2025-06-24 | -5.04 |
| 2025-06-23 | -5.22 |
| 2025-06-20 | -5.34 |
| 2025-06-18 | -5.42 |
| 2025-06-17 | -4.84 |
| 2025-06-16 | -5.23 |
| 2025-06-13 | -4.42 |
| 2025-06-12 | -4.08 |
| 2025-06-11 | -2.74 |
| 2025-06-10 | -2.65 |
| 2025-06-09 | -2.64 |
| 2025-06-06 | -2.76 |
| 2025-06-05 | -1.97 |
| 2025-06-04 | -1.89 |
| 2025-06-03 | -1.92 |
| 2025-06-02 | -1.86 |
| 2025-05-30 | -1.65 |
| 2025-05-29 | -1.55 |
| 2025-05-28 | -1.58 |
| 2025-05-27 | -1.54 |
| 2025-05-23 | -1.63 |
| 2025-05-22 | -1.59 |
| 2025-05-21 | -1.63 |
| 2025-05-20 | -2.82 |
| 2025-05-19 | -2.97 |
| 2025-05-16 | -2.74 |
| 2025-05-15 | -3.64 |
| 2025-05-14 | -3.65 |
| 2025-05-13 | -3.74 |
| 2025-05-12 | -4.10 |
| 2025-05-09 | -3.83 |
| 2025-05-08 | -3.93 |
| 2025-05-07 | -3.74 |
| 2025-05-06 | -3.58 |
| 2025-05-05 | -4.03 |
| 2025-05-02 | -4.23 |
| 2025-05-01 | -4.19 |
| 2025-04-30 | -4.28 |
| 2025-04-29 | -3.96 |
| 2025-04-28 | -4.14 |
| 2025-04-25 | -3.65 |
| 2025-04-24 | -3.73 |
| 2025-04-23 | -3.77 |